Oramed to Raise $15,800,000 in Registered Direct Offering

JERUSALEM, Dec. 24, 2013 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price of $10.00 per […]

Categories: 新闻通稿|Tags: |

Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes

Company Additionally Anticipates Results from Phase 2a FDA Study for Type 2 Diabetes in January

JERUSALEM, Dec. 20, 2013 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a […]

Categories: 新闻通稿|Tags: |

Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel

JERUSALEM, December 10, 2013 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM:ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received allowance for a key patent from the Israeli Patent Office. The patent, entitled “Methods and Compositions […]

Categories: 新闻通稿|Tags: |

Oramed Receives Patent in the European Union for the Oral Delivery of Insulin

JERUSALEM, Nov. 19, 2013 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the European Patent Office has allowed the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.”

Europe is one […]

Categories: 新闻通稿|Tags: |

Oramed Announces Last Patient Out in Phase 2a FDA Trial of its ORMD-0801 Oral Insulin Capsule

JERUSALEM, November 12, 2013 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the last patient has left the clinic from its U.S. FDA Phase 2a safety study for ORMD-0801, an […]

Categories: 新闻通稿|Tags: |

Oramed Granted Patents in Japan and Canada for its POD™ Technology for the Oral Delivery of Proteins

Increases patent portfolio to 11 issued and 24 pending

JERUSALEM, October 3, 2013 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a developer of oral drug delivery systems, announced today that it has received two additional patent approvals for its platform Protein Oral Delivery (POD™) technology in […]

Categories: 新闻通稿|Tags: |

Oramed to Participate in Barclays’ Israel Biotech Corporate Day in Zurich on September 30, 2013

JERUSALEM, September 25, 2013 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a developer of oral drug delivery systems, announced today that it has been invited to participate in an exclusive Israeli Biotech Corporate Day, hosted by Barclays on September 30, 2013 in Zurich, Switzerland.  The […]

Categories: 新闻通稿|Tags: |

Oramed’s Platform Technology in Oral Delivery of Proteins Receives Patent in Russia

This approval comes following last week’s announcement of patent approval in China

JERUSALEM, September 17, 2013 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a developer of oral drug delivery systems, announced today that it has been granted a patent from Russia’s Federal Service for Intellectual Property, […]

Categories: 新闻通稿|Tags: |

Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins

JERUSALEM, September 10, 2013 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent from the State Intellectual Property Office of the People’s Republic of China.

The patent, titled “Methods and […]

Categories: 新闻通稿|Tags: |

Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes

Company’s 2nd product slated for U.S. clinical trials offers a more patient-friendly form of GLP-1 analog which had more than $2 billion USD in 2012 sales

JERUSALEM, September 3, 2013 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://chinese.oramed.com), a developer of oral drug delivery systems, announced today […]

Categories: 新闻通稿|Tags: |